Ernexa Therapeutics (Nasdaq: ERNA) reported positive preliminary, disease-modifying preclinical results for ERNA-201 in a collagen-induced arthritis model and said the findings reinforce its synthetic induced mesenchymal stem cell (iMSC) platform. The company will pause additional preclinical spending on ERNA-201 while directing near-term resources to ERNA-101, its lead oncology candidate engineered to express an IL-7/IL-15 fusion cytokine. Ernexa is targeting a U.S. Food and Drug Administration investigational new drug application submission for ERNA-101 in the fourth quarter of 2026, with clinical data currently expected in the fourth quarter of 2027, and President and Chief Executive Officer Sanjeev Luther is scheduled to present the company's oncology strategy at the H.C. Wainwright 28th Annual Global Investment Conference in New York City on September 16, 2026. ERNA-201 remains available for future development, while the company cautioned that its development plans and other forward-looking statements are subject to risks and uncertainties.